Thank you for your interest in NovoPen Echo®. Please contact Novo Nordisk in your local country to learn more about NovoPen Echo®. Local contact information is available on the country specific Novo Nordisk websites.
APROM ID#: 2801; approval date: January 2011
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries.
 | Novo Nordisk in the USA |
 | Novo Nordisk in Denmark |
Or choose:
